Compare Bristol-Myers Squibb Co (BMY) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Ross Stores, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Ross Stores, Inc. trades at $221.99 (market cap $70.87B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | ROST | |
|---|---|---|
Market Cap | $116.30B | $70.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $240.13 |
52-Week Low | $42.60 | $127.59 |
Enterprise Value | $152.24B | $71.46B |
Dividend Yield | 4.42% | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Ross Stores (ROST) trades at $219.46, down 1.53% on the day, with a bullish technical outlook supported by moving averages and consistent earnings beats. The company demonstrates strong profitability with a 9.74% net margin and 38.98% ROE, while revenue grew to $21.13B in 2025. Recent news highlights robust Q1 2026 performance with 21% sales growth and expanding margins.
The stock offers upside to the $259 consensus price target, driven by operational efficiency and store expansion. Risks include consumer spending sensitivity and competitive pressures. Analyst sentiment is strongly positive with 64% buy ratings, though valuation multiples like the 30.65 P/E warrant monitoring amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
